The Effect of PC945 on Aspergillus or Candida Lung Infections in Patients With Asthma or Chronic Respiratory Diseases

Exclusion Criteria

• •1. Subjects who have received more than 2 weeks of intravenous (IV), oral or inhaled antifungal therapy within 6 months prior to Visit 3 or any antifungal therapy (IV, oral or inhaled) within 2 months of Visit 3.
• •2. Subjects taking medication that could significantly increase the risks of AEs with triazoles.
• •3. Subjects who are receiving antiretroviral protease inhibitors.
• •4. Clinical or laboratory evidence of bacterial bronchitis at the point of screening.
• •5. Subjects who have used an experimental medical device or received an experimental drug within 3 months or within a period less than five times the experimental drug's half-life, whichever is longer, before the first dose of the study drug is scheduled.
• •6. Clinically significant screening abnormalities (including, but not limited to, vital signs, ECG, laboratory tests, physical examination and spirometry) that, in the Investigator's opinion, exclude the subject from participation in the study.
• •7. Positive test at screening for hepatitis B virus infection, or antibodies to hepatitis C virus.
• •8. If female, the subject is pregnant (e.g. has a positive serum β human chorionic gonadotropin at screening or a positive urinary pregnancy test pre-dose on Day 1), lactating or breast feeding.
• •9. Subject is an employee or a first-degree relative of anyone employed by Pulmocide, a participating clinical trial site, or any contract research organisation involved in the study.
• •10. Any other reason that the Investigator considers makes the subject unsuitable to participate.